ASFV

Statement of the ASFV Committee on Ruling in Delaware Action

Retrieved on: 
Tuesday, November 1, 2022

The ASFV Committee fundamentally disagrees with the ruling and the Courts conclusions as to matters of fact and law.

Key Points: 
  • The ASFV Committee fundamentally disagrees with the ruling and the Courts conclusions as to matters of fact and law.
  • However, given the late date of the ruling and the imminent annual meeting to be held on November 3, 2022, the ASFV Committee does not currently intend to proceed to trial or seek an appeal.
  • While it is terribly unfortunate that the board appears to have avoided accountability to stockholders, the ASFV Committee has limited recourse at this time and thus will not continue with the Delaware action.
  • THE ASFV COMMITTEE STRONGLY ADVISES ALL STOCKHOLDERS OF AIM TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY CONTAIN IMPORTANT INFORMATION.

ASFV Committee Reveals Troubling Statements Made by Entrenched AIM Board Uncovered Through Discovery in Delaware Action

Retrieved on: 
Monday, October 24, 2022

We believe the entrenched AIM Boards statements about stockholders, expectation for excessive compensation, and tactics to deny any stockholder nomination are truly reprehensible, stated the ASFV Committee.

Key Points: 
  • We believe the entrenched AIM Boards statements about stockholders, expectation for excessive compensation, and tactics to deny any stockholder nomination are truly reprehensible, stated the ASFV Committee.
  • The Boards actions, before the ASFV nomination and since, clearly demonstrate that they are breaching their fiduciary duties to the Company and its stockholders.
  • We believe it is clear that this entrenched Board is not putting the interests of the Company and its stockholders first in making decisions and evaluating opportunities.
  • Notwithstanding the foregoing, the incumbent Board members have never once considered expanding the Board or hiring executives with relevant experience to help run AIM.

U.S. District Court Dismisses AIM’s "Baseless" Section 13(d) Claim

Retrieved on: 
Thursday, October 13, 2022

NEW YORK, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Jonathan Jorgl, an AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) stockholder, together with his nominees, Robert L. Chioini and Michael Rice (collectively, the “AIM Stockholder Full Value Committee” or the “ASFV Committee”), today announced that the U.S. District Court, Middle District of Florida, dismissed in its entirety, without prejudice, the action brought by AIM (the “Florida Action”) against the members of the ASFV Committee and other individuals baselessly alleging that the members of the ASFV Committee were acting as a group with certain stockholders of AIM in violation of Section 13(d) of the Securities Exchange Act of 1934.

Key Points: 
  • The court ruled that AIM lacked standing to bring the claim based on long-standing binding precedent.
  • Further, [t]he threat of this sort of litigation might remove from the field a player whose self-interest is to monitor management.
  • Until the court rules, stockholders should not be distracted by cherry-picked, incomplete and misleading information disseminated by the incumbent board.
  • Investors can also contact Alliance Advisors at the telephone number or email address set for the above.

AIM Stockholder Full Value Committee Reiterates Intent to Proceed with Nominations and Proxy Solicitation

Retrieved on: 
Tuesday, August 16, 2022

NEW YORK, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Jonathan Jorgl, an AIM ImmunoTech Inc. (NYSE American: AIM), (“AIM”) stockholder, together with his nominees, Robert L. Chioini and Michael Rice (collectively, the “AIM Stockholder Full Value Committee” or the “ASFV Committee”), today reiterated their commitment to proceed with the solicitation of proxies for the election of Mr. Chioini and Mr. Rice to the AIM board of directors at the upcoming 2022 annual meeting.

Key Points: 
  • Therefore, AIM is prevented from proceeding with the annual meeting and blocking the nominations of Mr. Chioini and Mr. Rice prior to a court ruling.
  • THE ASFV COMMITTEE STRONGLY ADVISES ALL STOCKHOLDERS OF AIM TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION.
  • IN ADDITION, THE PARTICIPANTS IN THIS PROXY SOLICITATION WILL PROVIDE COPIES OF THE PROXY STATEMENT WITHOUT CHARGE, WHEN AVAILABLE, UPON REQUEST.
  • The participants in the proxy solicitation are expected each to be member of the ASFV Committee and River Rock Advisors LLC (collectively, the Participants).

AIM Stockholder Full Value Committee Announces Director Nominations for AIM Annual Meeting and Confirms Intent to Proceed with Proxy Solicitation

Retrieved on: 
Thursday, July 21, 2022

Notwithstanding meritless claims to the contrary by AIM, the Notice is valid and complied with AIMs bylaws.

Key Points: 
  • Notwithstanding meritless claims to the contrary by AIM, the Notice is valid and complied with AIMs bylaws.
  • As such, the AIM Stockholder Full Value Committee intends to file a preliminary proxy statement with the SEC in due course and solicit proxies for the election of Mr. Chioini and Mr. Rice at AIMs annual meeting of stockholders.
  • IN ADDITION, THE PARTICIPANTS IN THIS PROXY SOLICITATION WILL PROVIDE COPIES OF THE PROXY STATEMENT WITHOUT CHARGE, WHEN AVAILABLE, UPON REQUEST.
  • The participants in the proxy solicitation are expected each to be member of the ASFV Committee and River Rock Advisors LLC (collectively, the Participants).

ATCC Announces Two Projects from the U.S. Department of Agriculture’s Chief Scientific In-House Research Agency, the Agricultural Research Service

Retrieved on: 
Tuesday, April 12, 2022

For the second project, ATCC will create genetically modified cell lines capable of growing and producing African Swine Fever Virus (ASFV) vaccines.

Key Points: 
  • For the second project, ATCC will create genetically modified cell lines capable of growing and producing African Swine Fever Virus (ASFV) vaccines.
  • Through these two projects, we will continue to support the USDA and strive to help the ARS achieve its mission of delivering scientific solutions to national and global agricultural challenges, said Raymond H. Cypess, D.V.M., Ph.D., chairman and CEO of ATCC.
  • African Swine Fever is a devastating disease of domestic and feral swine and causes a significant economic impact on the agricultural industry.
  • ATCC is a 501(c)3 nonprofit organization with headquarters in Manassas, Virginia, and a research and technology center of excellence in Gaithersburg, Maryland.

Tetracore, Inc. Introduces First USDA-Licensed Real-Time PCR Test for the Detection of African Swine Fever Virus in Swine Whole Blood and Spleen Samples

Retrieved on: 
Thursday, November 4, 2021

ROCKVILLE, Md., Nov. 4, 2021 /PRNewswire/ -- Tetracore, Inc. (Tetracore) announced today the licensing of their VetAlert™ African Swine Fever Virus (ASFV) DNA Diagnostic Test Kit by the United States Department of Agriculture (USDA) Center for Veterinary Biologics (CVB). It is the first USDA licensed diagnostic product for ASFV and is manufactured in the United States, critical for a rapid response in the event of an ASF outbreak.  Additionally, this diagnostic Kit provides animal health first responders with a critical tool to mitigate the potentially catastrophic economic and animal welfare impacts of an ASFV outbreak.

Key Points: 
  • ROCKVILLE, Md., Nov. 4, 2021 /PRNewswire/ --Tetracore, Inc. ( Tetracore ) announced today the licensing of their VetAlert African Swine Fever Virus (ASFV) DNA Diagnostic Test Kit by the United States Department of Agriculture (USDA) Center for Veterinary Biologics (CVB).
  • The VetAlert ASFV DNA high-performance test Kit was developed by Tetracore scientists and will be commercialized and sold by Tetracore.
  • Tetracore is a biotechnology company specializing in the development and manufacture of diagnostic devices and assays for the detection of infectious diseases.
  • Tetracore is a Registered Trademark and VetAlert is a Trademark of Tetracore, Inc.
    View original content to download multimedia: https://www.prnewswire.com/news-releases/tetracore-inc-introduces-first-...

Tetracore, Inc. Introduces First USDA-Licensed Real-Time PCR Test for the Detection of African Swine Fever Virus in Swine Whole Blood and Spleen Samples

Retrieved on: 
Thursday, November 4, 2021

ROCKVILLE, Md., Nov. 4, 2021 /PRNewswire/ -- Tetracore, Inc. (Tetracore) announced today the licensing of their VetAlert™ African Swine Fever Virus (ASFV) DNA Diagnostic Test Kit by the United States Department of Agriculture (USDA) Center for Veterinary Biologics (CVB). It is the first USDA licensed diagnostic product for ASFV and is manufactured in the United States, critical for a rapid response in the event of an ASF outbreak.  Additionally, this diagnostic Kit provides animal health first responders with a critical tool to mitigate the potentially catastrophic economic and animal welfare impacts of an ASFV outbreak.

Key Points: 
  • The Tetracore Real-Time PCR Test was validated for use on epithelial and serum samples.
  • ROCKVILLE, Md., Nov. 4, 2021 /PRNewswire/ --Tetracore, Inc. ( Tetracore ) announced today the licensing of their VetAlert African Swine Fever Virus (ASFV) DNA Diagnostic Test Kit by the United States Department of Agriculture (USDA) Center for Veterinary Biologics (CVB).
  • The VetAlert ASFV DNA high-performance test Kit was developed by Tetracore scientists and will be commercialized and sold by Tetracore.
  • Tetracore is a biotechnology company specializing in the development and manufacture of diagnostic devices and assays for the detection of infectious diseases.

Commercial Adoption of Herdscreen® ASFV Antibody Test in Europe

Retrieved on: 
Thursday, October 28, 2021

Herdscreen ASFV is a point-of-care rapid diagnostic test that identifies animals which have been exposed to the African Swine Fever Virus (ASFV) using whole blood, plasma or serum samples.

Key Points: 
  • Herdscreen ASFV is a point-of-care rapid diagnostic test that identifies animals which have been exposed to the African Swine Fever Virus (ASFV) using whole blood, plasma or serum samples.
  • Herdscreen uses a highly specific antigen produced using CrisBio, Algenex proprietary Baculovirus vector-mediated expression platform that uses insects as natural single-use bioreactors for the production of recombinant proteins.
  • This antigen is able to capture antibodies developed during infection with ASFV with 100% specificity and higher sensitivity than a commercial ELISA test, as evidenced in field and experimental samples from infected animals gathered by the European Union Reference Laboratory for African Swine Fever (CISA-INIA)1.
  • The adoption of Herdscreen ASFV by a major Spanish meat producer highlights the value of the test which resides in its ability to allow rapid individual testing in situ and aid in the certification of ASFV-infection status through the entire food supply chain.

USDA’s Vaccine Candidate Successful in Blocking Spread of African Swine Fever Virus

Retrieved on: 
Thursday, September 30, 2021

The majority of swine used in the global food supply are produced in Asia, where the virus has been causing outbreaks and devastating losses to the swine industry.

Key Points: 
  • The majority of swine used in the global food supply are produced in Asia, where the virus has been causing outbreaks and devastating losses to the swine industry.
  • African Swine Fever (ASF) was originally detected in 2007 in the Republic of Georgia and is known to cause virulent, deadly disease outbreaks in wild and domesticated swine.
  • Although the virus is causing profound economic losses to the swine industry, there have not been any outbreaks in the United States .
  • The findings also show that a commercial partner can replicate experimental level results and prevent the spread of the virus.